Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

Fig. 3

CMVSTs expressing iCHAR can reduce activation of responder alloreactive T-cells. a Representative dot plots showing activation of gated responder T-cells assessed by CD71 staining on Day 8. CD8 and CD4 subsets were gated and analyzed separately. b Quantification of CD71 + T-cells for both CD8 and CD4 subsets on Day 8 (mean ± SEM, n = 3). Significance was determined by paired two-tailed Student’s t-test. *p < 0.05 compared to NT CMVST condition. R responder, S stimulator

Back to article page